Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
More News related to ABMD
- Abiomed to Present at the 21st Annual Piper Jaffray Healthcare Conference
- Lazard Capital Downgrades Abiomed (ABMD) to Hold
- Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
- Abiomed Announces Record Revenue of $20 Million for Second Quarter of Fiscal 2010
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Earnings
- Wedbush Initiates Coverage on Delcath Systems (DCTH) with an Outperform
- Sterne Agee Initiates Coverage on Boise (BZ) with a Buy
- Sandler O'Neill Initiates Coverage on Wilshire Bancorp (WIBC) with a Hold
- Cowen & Co Initiates Coverage on Delcath Systems (DCTH) with an Outperform
- WBB Securities Initiates Coverage on Electro-Optical Sciences (MELA) with a Sell
Abiomed, Inc. (NASDAQ: ABMD) reports Q2 loss of $0.21, even with the analyst estimate of ($0.21). Revenue for the quarter was $20.02 million, which compares to the estimate of $20.14 million.
Related Categories
EarningsStocks Mentioned
-0.39Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
